The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Feb 13

PMID 39941797

Authors

Mitsunobu Takeda

Shoma Yoshida

Takuya Inoue

Yuki Sekido

Tsuyoshi Hata

Atsushi Hamabe

Takayuki Ogino

Norikatsu Miyoshi

Mamoru Uemura

Hirofumi Yamamoto

Yuichiro Doki

Hidetoshi Eguchi

Affiliations

Soon will be listed here.

Abstract

: Colorectal cancer (CRC) remains a leading cause of cancer mortality globally, with KRAS mutations occurring in 30-40% of cases, contributing to poor prognosis and resistance to anti-EGFR therapy. This review explores the biological significance, clinical implications, and therapeutic targeting of KRAS mutations in CRC. : A comprehensive analysis of the existing literature and clinical trials was performed, highlighting the role of KRAS mutations in CRC pathogenesis, their impact on prognosis, and recent advancements in targeted therapies. Specific attention was given to emerging therapeutic strategies and resistance mechanisms. : KRAS mutations drive tumor progression through persistent activation of MAPK/ERK and PI3K/AKT signaling pathways. These mutations influence the tumor microenvironment, cancer stem cell formation, macropinocytosis, and cell competition. KRAS-mutant CRC exhibits poor responsiveness to anti-EGFR monoclonal antibodies and demonstrates primary and acquired resistance to KRAS inhibitors. Recent breakthroughs include the development of KRAS G12C inhibitors (sotorasib and adagrasib) and promising agents targeting G12D mutations. However, response rates in CRC remain suboptimal compared to other cancers, necessitating combination therapies and novel approaches, such as vaccines, nucleic acid-based therapeutics, and macropinocytosis inhibitors. : KRAS mutations are central to CRC pathogenesis and present a significant therapeutic challenge. Advances in KRAS-targeted therapies offer hope for improved outcomes, but resistance mechanisms and organ-specific differences limit efficacy. Continued efforts in personalized treatment strategies and translational research are critical for overcoming these challenges and improving patient survival.

References

Mukhopadhyay S, Vander Heiden M, McCormick F . The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. Nat Cancer. 2021; 2(3):271-283. PMC: 8045781. DOI: 10.1038/s43018-021-00184-x. View

Kim M, Lee H, Kim J, Kim Y, Kwon J, Lee J . Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer. 2012; 12:347. PMC: 3488475. DOI: 10.1186/1471-2407-12-347. View

Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D . The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019; 575(7781):217-223. DOI: 10.1038/s41586-019-1694-1. View

Osumi H, Shinozaki E, Nakamura Y, Esaki T, Yasui H, Taniguchi H . Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. Nat Commun. 2024; 15(1):5885. PMC: 11246505. DOI: 10.1038/s41467-024-50026-4. View

Moore A, Rosenberg S, McCormick F, Malek S . RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov. 2020; 19(8):533-552. PMC: 7809886. DOI: 10.1038/s41573-020-0068-6. View

Nakai K, Lin H, Yamano S, Tanaka S, Kitamoto S, Saitoh H . Wnt activation disturbs cell competition and causes diffuse invasion of transformed cells through NF-κB-MMP21 pathway. Nat Commun. 2023; 14(1):7048. PMC: 10624923. DOI: 10.1038/s41467-023-42774-6. View

Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N . A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009; 15(6):489-500. PMC: 2743093. DOI: 10.1016/j.ccr.2009.03.022. View

Takeda M, Koseki J, Takahashi H, Miyoshi N, Nishida N, Nishimura J . Disruption of Endolysosomal RAB5/7 Efficiently Eliminates Colorectal Cancer Stem Cells. Cancer Res. 2019; 79(7):1426-1437. DOI: 10.1158/0008-5472.CAN-18-2192. View

Watanabe T, Yoshino T, Uetake H, Yamazaki K, Ishiguro M, Kurokawa T . KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol. 2013; 43(7):706-12. DOI: 10.1093/jjco/hyt062. View

10.

Moreno E, Basler K, Morata G . Cells compete for decapentaplegic survival factor to prevent apoptosis in Drosophila wing development. Nature. 2002; 416(6882):755-9. DOI: 10.1038/416755a. View

11.

Bartoschek M, Oskolkov N, Bocci M, Lovrot J, Larsson C, Sommarin M . Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018; 9(1):5150. PMC: 6279758. DOI: 10.1038/s41467-018-07582-3. View

12.

Li M, Diehl F, Dressman D, Vogelstein B, Kinzler K . BEAMing up for detection and quantification of rare sequence variants. Nat Methods. 2006; 3(2):95-7. DOI: 10.1038/nmeth850. View

13.

Albanese I, Scibetta A, Migliavacca M, Russo A, Bazan V, Tomasino R . Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004; 325(3):784-91. DOI: 10.1016/j.bbrc.2004.10.111. View

14.

Pai E, Krengel U, Petsko G, Goody R, Kabsch W, Wittinghofer A . Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis. EMBO J. 1990; 9(8):2351-9. PMC: 552258. DOI: 10.1002/j.1460-2075.1990.tb07409.x. View

15.

Milburn M, Tong L, Devos A, Brunger A, Yamaizumi Z, Nishimura S . Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science. 1990; 247(4945):939-45. DOI: 10.1126/science.2406906. View

16.

Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1065-75. DOI: 10.1016/S1470-2045(14)70330-4. View

17.

Scheffzek K, Ahmadian M, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F . The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997; 277(5324):333-8. DOI: 10.1126/science.277.5324.333. View

18.

Adachi Y, Kimura R, Hirade K, Yanase S, Nishioka Y, Kasuga N . Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nat Cancer. 2023; 4(6):829-843. DOI: 10.1038/s43018-023-00575-2. View

19.

Wang X, Allen S, Blake J, Bowcut V, Briere D, Calinisan A . Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Inhibitor. J Med Chem. 2021; 65(4):3123-3133. DOI: 10.1021/acs.jmedchem.1c01688. View

20.

Janes M, Zhang J, Li L, Hansen R, Peters U, Guo X . Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018; 172(3):578-589.e17. DOI: 10.1016/j.cell.2018.01.006. View